Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Zuranolone proven to be effective against symptoms of postpartum depression

Staff Writer
Staff Writer 11 months ago
Updated 2021/07/01 at 12:53 AM
Share
SHARE

In a recently published study publicized in JAMA Psychiatry, a team of American researchers from New York, North Carolina, and Massachusetts tested the use of an experimental treatment known as zuranolone.

According to their findings, researchers found that zuranolone could be effective for treating symptoms associated with postpartum depression (PPD).

The study investigated its use among women in early to mid-adulthood, between the ages of 18 and 45, with no later than six months of postpartum.

Researchers used the 17-item Hamilton Rating Scale for Depression (HAMD-17) score to measure symptoms upon the use of zuranolone. 76 participants were given a placebo, while 77 received 30 mg of zuranolone, taken each evening for a span of two weeks.

The investigation unveiled a day 15 improvement based on their measurements using the HAMD-17 scores, comparing the drug’s use with placebo.

All in all, the randomized clinical trial of zuranolone may be an effective means for treating postpartum depression, with further testing of the treatment necessary.

“In this randomized clinical trial, zuranolone improved the core symptoms of depression as measured by HAMD-17 scores in women with PPD and was generally well tolerated, supporting further development of zuranolone in the treatment of PPD,” researchers determined in their JAMA report.

You Might Also Like

Study finds vitamin D does not reduce risk of type 2 diabetes

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

TAGGED: maternal health, Zuranolone, postpartum depression
Staff Writer June 30, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article E-cigarettes could be more beneficial than nicotine replacement treatment for smokers
Next Article Many Americans believe in intelligent life outside of Earth but no threat to national security: survey

Recommended

Clinical

Study finds vitamin D does not reduce risk of type 2 diabetes

2 Min Read
Clinical

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

1 Min Read
Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?